Jasper Therapeutics, Inc., (JSPR): Price and Financial Metrics
GET POWR RATINGS... FREE!
JSPR Stock Price Chart Interactive Chart >
JSPR Price/Volume Stats
| Current price | $1.74 | 52-week high | $5.81 |
| Prev. close | $1.80 | 52-week low | $0.39 |
| Day low | $1.72 | Volume | 1,073,872 |
| Day high | $1.81 | Avg. volume | 10,522,528 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $1.73 | Market Cap | 66.09M |
Jasper Therapeutics, Inc., (JSPR) Company Bio
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Latest JSPR News From Around the Web
Below are the latest news stories about JASPER THERAPEUTICS INC that investors may wish to consider to help them evaluate JSPR as an investment opportunity.
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common StockREDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each shar |
Jasper Therapeutics Announces Proposed Public Offering of Common StockREDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common sto |
Why Is Jasper Therapeutics (JSPR) Stock Up 50% Today?JSPR stock is shooting higher as Jasper Therapeutics helps to combat the life-threatening impact of certain blood diseases. |
APRN Stock Alert: Short Squeeze Takes Blue Apron Back Above $1Blue Apron (APRN) stock has investors excited on Friday as the company's shares increased above the $1 NYSE minimum requirement. |
AVCT Stock Alert: Is American Virtual Cloud the Next Big Squeeze?American Virtual Cloud Technologies (AVCT) stock is on the minds of traders with some wondering what's next for the company. |
JSPR Price Returns
| 1-mo | 195.17% |
| 3-mo | 133.56% |
| 6-mo | -7.94% |
| 1-year | -60.09% |
| 3-year | -82.34% |
| 5-year | N/A |
| YTD | 260.32% |
| 2022 | -93.85% |
| 2021 | -21.58% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...